Clarivate Q3 revenue falls 9.2% to $481.6m
Key points
- Clarivate reported third-quarter continuing-operations revenue of $481.6 million, down 9.2% year over year, primarily reflecting business disposals.
- Net loss including discontinued operations widened to $80.8 million from $28.3 million, while adjusted diluted earnings increased to $0.21 per share.
- Clarivate completed the Life Sciences & Healthcare divestiture in October and expects full-year continuing-operations revenue of $1.965 billion–$1.985 billion.
Clarivate (NYSE:CLVT) reported third-quarter 2026 continuing-operations revenue of $481.6 million, down 9.2% year over year, primarily reflecting the impact of business disposals.
Organic revenue increased 0.4% and organic recurring revenue rose 1.3%, while adjusted diluted earnings per share improved to $0.21 from $0.18 a year earlier.
The company's net loss, including discontinued operations, widened to $80.8 million from $28.3 million, reflecting a $62.2 million non-cash goodwill impairment associated with its Life Sciences & Healthcare business.
Clarivate generated $233.1 million in free cash flow during the first nine months of 2026, including discontinued operations, representing a 15.6% decline, while debt outstanding totaled $4.176 billion at September 30.
The company expects full-year continuing-operations revenue of $1.965 billion–$1.985 billion and adjusted EBITDA of $865 million–$885 million.
Clarivate completed the sale of its Life Sciences & Healthcare segment to Altaris on October 6, 2026, receiving $488.4 million in net cash proceeds to support debt reduction and financial flexibility.
The company now focuses on Academia & Government and Intellectual Property, providing research data, analytics, workflow software and intelligence services to universities, corporations and other organizations.
